Q3 2026 Materialise NV Financial Results Conference Call - MATERIALISE NV

Explicit Guidance:

• FY2026 Revenue: Reconfirms full-year revenue guidance of €273 million to €283 million, explicitly noting this range absorbs the unfavorable impact of recent divestitures (Fit & Eyewear).
• FY2026 Adjusted EBIT: Reconfirms full-year adjusted EBIT guidance of €12 million to €14 million, a range previously raised in August.
• Cash Flow & Capital Allocation: Maintaining "tight cost control" and "strong cash generation" while continuing to "increase investment in focus areas" (implying sustained CAPEX and R&D spending) for the remainder of 2026.

Business-Segment Outlook:

• Medical: Anticipates continued "real momentum" in personalized solutions; expects acceleration in growth opportunities driven by targeted R&D investments in Q4 2026. Specific growth drivers include cranio-maxillofacial reconstruction in Ukraine (treating hundreds of patients), new sterile packaging for CMS, and expanded AI workflows for cardiac and liver surgeries.
• Manufacturing: Projects "strong momentum" in series production (growing >30% YoY) continuing to drive the segment; notes a transition toward a "balanced situation" between series production and prototyping, with aerospace, defense, and semiconductor industries as key demand sources.
• Software: Faces continued "challenging industrial spending environment" with "extended sales cycles" expected to persist in Q4 due to the shift from prototyping to series manufacturing solutions (CoEM NPI); recurring revenue share expected to stabilize at ~84%.
• Motion (FITS Dynaprint): Expects continued volume growth in North America following Q3 expansion, building on the "significant increase in adoption" and demand for affordable orthotic solutions.

Market and Competitive Outlook:

• Competitive Dynamics: Management anticipates competitive pressures in the software sector due to "market pressures" and extended decision timelines, though they aim to differentiate via "open ecosystem" approaches and security features (e.g., Identify3D integration for part-level tracing).
• Market Trends: Observes a structural shift in customer behavior from prototyping to series production, necessitating more complex sales processes involving multi-team coordination.
• Demand Trends: Strong demand for "high-value series production" in defense and aerospace; growing need for "personalized care" and "3D visualization" training in war-affected regions (Ukraine).

Macro / Industry Outlook:

• Economic Environment: Management acknowledges "cautious customer spending" in the industrial software sector and extended sales cycles as key macro/industry headwinds.
• Regulatory/Safety: Anticipates increased regulatory compliance needs driving demand for sterile packaging and traceability solutions.
• Geopolitical: The ongoing war in Ukraine is identified as a specific catalyst for increased demand for cranio-maxillofacial reconstructive solutions.

Strategic Initiatives:

• Capacity Additions: Completed investments in additional metal additive manufacturing capabilities in Q3 to support "faster production of larger metal components" for defense and to generate data for software-based quality assurance.
• R&D Investment: Plans to continue "stepping up investments in innovation," particularly in the Medical segment, to capture "accelerating market opportunities" throughout Q4 2026.
• Events & Advocacy: Scheduled showcase of "open ecosystem" capabilities and advocacy for common additive manufacturing frameworks at Formnext (November) and the Euronext Tech Leaders Forum (December).
• M&A/Divestitures: Recent divestitures (Fit & Eyewear) fully absorbed into the financial guidance; no new M&A timing specified beyond current strategic partnerships (e.g., Superhuman Center).

Risks and Headwinds to Outlook:

• Sales Cycle Length: Extended sales cycles associated with selling series manufacturing solutions (CoEM) compared to traditional prototyping tools may dampen revenue velocity.
• Customer Spending: Continued "cautious customer spending" in the industrial software sector could pressure software revenue and margins.
• One-Time Costs: Previous quarters included one-time costs (inventory impairment); while not explicitly quantified for Q4, the guidance assumes continued "tight cost control" to offset potential volatility.
• Divestiture Impact: The financial guidance reflects the need to "fully absorb" the revenue loss from recent divestitures.

Management Tone on the Future:

• Confidence Level: "Confident" in delivering financial targets for FY2026 despite headwinds.
• Sentiment: Positive on long-term execution and market opportunities ("accelerating market opportunities"), cautious on short-term industrial software spending.
• Stance: Reaffirmation of guidance (rather than updating) signals high conviction in current strategic direction and cost discipline.

Miscellaneous:

• Share Buybacks: Program continued through Q3 2026 (€7.5m invested); no specific new buyback volume guidance provided, but "flexibility to invest" remains.
• Partnership Impact: The partnership with the Superhuman Center is expected to support "hundreds of patients" and build local medical expertise over the coming period.